Prosonix cashes in £17.1m
Enlarge image


Prosonix cashes in £17.1m

23.05.2012 - British respiratory medicines company Prosonix Ltd. has extended its Series B financing round to £17.1m.

Oxford – The lion’s share of the new capital comes from new investor Gimv, a leading European technology investor, who contributed £5.7m. The rest was contributed by the syndicate of investors that participated in the first closing of the round in June 2011. The syndicate includes Ventech, Gilde Healthcare Partners, Entrepreneurs Fund, Quest for Growth and Solon Ventures.

The Oxford-based Prosonix announced it will use the proceeds of the financing to push forward its product pipeline of inhalable mono- and combination therapies. “These new funds will enable Prosonix to accelerate its activities aimed at attaining key performance and clinical data for our pipeline of excipient-free, drug-only respiratory medicines”, said David Hipkiss, Prosonix' CEO. His company works on development programs for an inhaled corticosteroid for asthma and a long-acting muscarinic antagonist for chronic obstructive pulmonary disorder. Its unique Multi-component Particle (MCP™) platform enables Prosonix to combine two or more drug molecules consistently in a pre-determined ratio in each and every particle in the formulation.

Karl Nägler, Venture Capital Partner at new investor Gimv, will join the Prosonix board as a Non-executive Director. „We are confident that Prosonix can become a significant player in the area of respiratory medicines“ said Nägler, stressing that Prosonix is at an important point in its development.


26.11.2015 Bioeconomy movers and shakers from every corner of the globe met this week at the world’s first Global Bioeconomy Summit in Berlin to discuss, debate and define better ways to ensure the bioeconomy succeeds on an international level.


24.11.2015 After weeks of speculation it is official: US pharma major Pfizer and Irish Botox maker Allergan will merge. With the deal, Pfizer is planning to dodge the high US taxes, causing indignation among US politicians.


23.11.2015 Amidst talk of the IPO window closing and cancelled flotations, diagnostics firms are still striking a chord with investors. Swedish Immunovia and German Curetis are successfully raising public money.


20.11.2015 French Sanofi and British AstraZeneca are giving open innovation a go: The two pharma giants will exchange thousands of compounds – for free.


19.11.2015 French gene editing company Cellectis has granted Servier the rights to bring cancer immunotherapy UCART19 to market. Servier in turn has teamed up with Pfizer to hurry development along.


17.11.2015 The first Italian accelerator specifically for biotech projects has been launched with help from Sofinnova Partners. The plan of BiovelocITA: to help Italy grow into one of Europe’s strongest biotech markets.


13.11.2015 Scientists in Bath, UK, have developed a medical dressing that turns fluorescent green when it detects infection. The researchers hope that the smart burns dressing will help fight antibiotic resistance.


13.11.2015 Out with the old: Roche is discarding four sites with 1,200 staff in an effort to restructure its manufacturing network for small molecules. Instead, a new manufacturing site will be built in Switzerland.


10.11.2015 Algae have many skills, but cancer fighting was not one of them – until now. Researchers from Australia and Germany have genetically engineered diatom algae to accurately deliver chemotherapeutic drugs.


10.11.2015 AstraZeneca has plucked Californian biopharma company ZS Pharma from under Actelion’s nose. The UK company is paying US$2.7bn (€2.5bn) to acquire ZS and its promising hyperkalaemia treatment currently under US regulatory review.


All Events


Strasbourg (F)

BioFIT 2015

Current issue

All issues

Product of the week


Stock list

All quotes


  • EPIGENOMICS (D)2.26 EUR20.86%
  • SAREUM HOLDINGS (UK)0.21 GBP10.53%


  • THERAMETRICS (CH)0.04 CHF-20.00%
  • CO.DON (D)2.35 EUR-7.84%
  • DIAMYD MEDICAL -B- (S)9.40 SEK-6.00%


  • PLETHORA (UK)5.50 GBP76.3%
  • CELLECTIS (F)30.25 EUR34.9%
  • PROTHENA PLC (IE)73.19 USD34.8%


  • EPIGENOMICS (D)2.26 EUR-48.5%
  • EVOCUTIS (UK)0.09 GBP-40.0%


  • KARO BIO (S)37.80 SEK5300.0%
  • CHRONTECH PHARMA (S)0.34 SEK1600.0%
  • GALAPAGOS (B)46.32 EUR258.0%


  • BIOTEST (D)15.77 EUR-80.4%
  • EVOCUTIS (UK)0.09 GBP-78.6%

No liability assumed, Date: 27.11.2015